GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration

Area of Science:

• Endocrinology
• Cell Biology
• Diabetes Research

Background:

• Glucagon-like peptide-1 receptor (GLP1R) agonists and dipeptidyl peptidase 4 inhibitors are common diabetes treatments.
• These drugs stimulate insulin secretion and reduce caloric intake but do not increase human beta cell proliferation.
• Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitors can induce modest beta cell proliferation but lack specificity.

Purpose of the Study:

• To investigate the synergistic effect of combining GLP1R agonists and DYRK1A inhibitors on human beta cell proliferation.
• To determine if this combination enhances beta cell function and improves glucose control in vivo.
• To assess the safety and specificity of the combined treatment approach.

Main Methods:

• Human beta cells (normal and type 2 diabetic) were treated with combinations of GLP1R agonists and DYRK1A inhibitors.
• Beta cell proliferation, insulin secretion, and gene expression were analyzed.
• Human islets were transplanted into immunodeficient mice to evaluate in vivo efficacy and safety.

Main Results:

• The combination therapy synergistically increased human beta cell replication from ~2% to 5-6%.
• This synergy required DYRK1A inhibition, increased cAMP, and did not cause beta cell dedifferentiation.
• In vivo studies showed enhanced beta cell proliferation, insulin secretion, and glucose control in transplanted human islets.

Conclusions:

• Combining GLP1R agonists and DYRK1A inhibitors offers a synergistic strategy to enhance human beta cell proliferation and function.
• This approach shows promise for treating type 2 diabetes by increasing beta cell mass and improving glycemic control.
• The combination demonstrates improved beta cell specificity and safety in preclinical models.